Studies have demonstrated that CXCR2 inhibitors, including SB225002 and SX-682, and neutralizing antibodies can effectively block PMN-MDSCs infiltration, thereby slowing tumor progression and restoring responsiveness to immunotherapy in refractory cancer models (Figure 3C) [116,117,118]. This evidence concerns the gene CXCR2 and cancer.